These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

236 related items for PubMed ID: 16841083

  • 1. Challenge with mammary tumor cells expressing MHC class II and CD80 prevents the development of spontaneously arising tumors in MMTV-neu transgenic mice.
    Jabrane-Ferrat N, Campbell MJ, Esserman LJ, Peterlin BM.
    Cancer Gene Ther; 2006 Nov; 13(11):1002-10. PubMed ID: 16841083
    [Abstract] [Full Text] [Related]

  • 2. CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory.
    Mortara L, Castellani P, Meazza R, Tosi G, De Lerma Barbaro A, Procopio FA, Comes A, Zardi L, Ferrini S, Accolla RS.
    Clin Cancer Res; 2006 Jun 01; 12(11 Pt 1):3435-43. PubMed ID: 16740768
    [Abstract] [Full Text] [Related]

  • 3. Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain.
    Thompson JA, Dissanayake SK, Ksander BR, Knutson KL, Disis ML, Ostrand-Rosenberg S.
    Cancer Res; 2006 Jan 15; 66(2):1147-54. PubMed ID: 16424052
    [Abstract] [Full Text] [Related]

  • 4. DNA vaccines targeting tumor antigens to B7 molecules on antigen-presenting cells induce protective antitumor immunity and delay onset of HER-2/Neu-driven mammary carcinoma.
    Sloots A, Mastini C, Rohrbach F, Weth R, Curcio C, Burkhardt U, Jäger E, Forni G, Cavallo F, Wels WS.
    Clin Cancer Res; 2008 Nov 01; 14(21):6933-43. PubMed ID: 18980988
    [Abstract] [Full Text] [Related]

  • 5. Combination gene therapy with CD86 and the MHC class II transactivator in the control of lung tumor growth.
    Martin BK, Frelinger JG, Ting JP.
    J Immunol; 1999 Jun 01; 162(11):6663-70. PubMed ID: 10352284
    [Abstract] [Full Text] [Related]

  • 6. MMTV promoter hypomethylation is linked to spontaneous and MNU associated c-neu expression and mammary carcinogenesis in MMTV c-neu transgenic mice.
    Zhou H, Chen WD, Qin X, Lee K, Liu L, Markowitz SD, Gerson SL.
    Oncogene; 2001 Sep 20; 20(42):6009-17. PubMed ID: 11593408
    [Abstract] [Full Text] [Related]

  • 7. Irradiated CIITA-positive mammary adenocarcinoma cells act as a potent anti-tumor-preventive vaccine by inducing tumor-specific CD4+ T cell priming and CD8+ T cell effector functions.
    Mortara L, Frangione V, Castellani P, De Lerma Barbaro A, Accolla RS.
    Int Immunol; 2009 Jun 20; 21(6):655-65. PubMed ID: 19395374
    [Abstract] [Full Text] [Related]

  • 8. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.
    Wei H, Wang S, Zhang D, Hou S, Qian W, Li B, Guo H, Kou G, He J, Wang H, Guo Y.
    Clin Cancer Res; 2009 Jul 15; 15(14):4612-21. PubMed ID: 19584156
    [Abstract] [Full Text] [Related]

  • 9. Identification of tumorsphere- and tumor-initiating cells in HER2/Neu-induced mammary tumors.
    Liu JC, Deng T, Lehal RS, Kim J, Zacksenhaus E.
    Cancer Res; 2007 Sep 15; 67(18):8671-81. PubMed ID: 17875707
    [Abstract] [Full Text] [Related]

  • 10. Involvement of Notch1 in the development of mouse mammary tumors.
    Diévart A, Beaulieu N, Jolicoeur P.
    Oncogene; 1999 Oct 28; 18(44):5973-81. PubMed ID: 10557086
    [Abstract] [Full Text] [Related]

  • 11. In vitro and in vivo antisense-mediated growth inhibition of a mammary adenocarcinoma from MMTV-neu transgenic mice.
    Sacco MG, Barbieri O, Piccini D, Noviello E, Zoppé M, Zucchi I, Frattini A, Villa A, Vezzoni P.
    Gene Ther; 1998 Mar 28; 5(3):388-93. PubMed ID: 9614559
    [Abstract] [Full Text] [Related]

  • 12. Effect of the silybin-phosphatidylcholine complex (IdB 1016) on the development of mammary tumors in HER-2/neu transgenic mice.
    Provinciali M, Papalini F, Orlando F, Pierpaoli S, Donnini A, Morazzoni P, Riva A, Smorlesi A.
    Cancer Res; 2007 Mar 01; 67(5):2022-9. PubMed ID: 17332330
    [Abstract] [Full Text] [Related]

  • 13. Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice.
    Sakai Y, Morrison BJ, Burke JD, Park JM, Terabe M, Janik JE, Forni G, Berzofsky JA, Morris JC.
    Cancer Res; 2004 Nov 01; 64(21):8022-8. PubMed ID: 15520211
    [Abstract] [Full Text] [Related]

  • 14. Spontaneous mammary tumors differ widely in their inherent sensitivity to adoptively transferred T cells.
    Wall EM, Milne K, Martin ML, Watson PH, Theiss P, Nelson BH.
    Cancer Res; 2007 Jul 01; 67(13):6442-50. PubMed ID: 17616705
    [Abstract] [Full Text] [Related]

  • 15. Differential expression of MHC class II molecules in highly metastatic breast cancer cells is mediated by the regulation of the CIITA transcription Implication of CIITA in tumor and metastasis development.
    Shi B, Vinyals A, Alia P, Broceño C, Chen F, Adrover M, Gelpi C, Price JE, Fabra A.
    Int J Biochem Cell Biol; 2006 Jul 01; 38(4):544-62. PubMed ID: 16343978
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Cooperative effects of Mycobacterium tuberculosis Ag38 gene transduction and interleukin 12 in vaccination against spontaneous tumor development in proto-neu transgenic mice.
    Sfondrini L, Rodolfo M, Singh M, Colombo MP, Colnaghi MI, Ménard S, Balsari A.
    Cancer Res; 2000 Jul 15; 60(14):3777-81. PubMed ID: 10919650
    [Abstract] [Full Text] [Related]

  • 18. HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice.
    Reilly RT, Gottlieb MB, Ercolini AM, Machiels JP, Kane CE, Okoye FI, Muller WJ, Dixon KH, Jaffee EM.
    Cancer Res; 2000 Jul 01; 60(13):3569-76. PubMed ID: 10910070
    [Abstract] [Full Text] [Related]

  • 19. Prevention of spontaneous neu-expressing mammary tumor development in mice transgenic for rat proto-neu by DNA vaccination.
    Pupa SM, Invernizzi AM, Forti S, Di Carlo E, Musiani P, Nanni P, Lollini PL, Meazza R, Ferrini S, Menard S.
    Gene Ther; 2001 Jan 01; 8(1):75-9. PubMed ID: 11402305
    [Abstract] [Full Text] [Related]

  • 20. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.
    Cabodi S, Tinnirello A, Di Stefano P, Bisarò B, Ambrosino E, Castellano I, Sapino A, Arisio R, Cavallo F, Forni G, Glukhova M, Silengo L, Altruda F, Turco E, Tarone G, Defilippi P.
    Cancer Res; 2006 May 01; 66(9):4672-80. PubMed ID: 16651418
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.